LYSOPADOL 17.86 Mg/Ml Oromucosal Spray

Nchi: Ayalandi

Lugha: Kiingereza

Chanzo: HPRA (Health Products Regulatory Authority)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
04-06-2016
Tabia za bidhaa Tabia za bidhaa (SPC)
15-06-2016

Viambatanisho vya kazi:

AMBROXOL HYDROCHLORIDE

Inapatikana kutoka:

Boehringer Ingelheim Limited

ATC kanuni:

R02AD

INN (Jina la Kimataifa):

AMBROXOL HYDROCHLORIDE

Kipimo:

17.86 Mg/Ml

Dawa fomu:

Oromucosal Spray

Dawa ya aina:

Product not subject to medical prescription

Eneo la matibabu:

ANESTHETICS, LOCAL

Idhini hali ya:

Authorised

Idhini ya tarehe:

2014-02-14

Taarifa za kipeperushi

                                1.  WHAT LYSOPADOL SPRAY IS AND WHAT IT IS  
USED FOR
t-ZTPQBEPM4QSBZDPOUBJOTUIFBDUJWFTVCTUBODFBNCSPYPM
IZESPDIMPSJEF5IFBDUJWFTVCTUBODFJTUIFQBSUPGUIFTQSBZ
UIBUHJWFTUIFUIFSBQFVUJDFGGFDUZPVOFFE
t-ZTPQBEPM4QSBZIBTBMPDBMBOBFTUIFUJDFGGFDUXIJDISFMJFWFT
UIFQBJOJOBDVUFTPSFUISPBU
t-ZTPQBEPM4QSBZJTVTFEUPSFMJFWFUIFQBJOJOBDVUFTPSF
UISPBUGPSBEVMUTBOEDIJMESFOPWFSZFBSTPGBHF
t:PVNVTUUBMLUPBEPDUPSJGZPVEPOPUGFFMCFUUFSPSJGZPV
GFFMXPSTFBGUFSEBZT
2.  WHAT YOU NEED TO KNOW BEFORE YOU TAKE
LYSOPADOL SPRAY
DO NOT TAKE LYSOPADOL SPRAY:
t*GZPVBSFBMMFSHJDUPBNCSPYPMIZESPDIMPSJEFPSBOZPGUIF
PUIFSJOHSFEJFOUTPGUIJTNFEJDJOF MJTUFEJOTFDUJPO 
WARNINGS AND PRECAUTIONS
5BMLUPZPVSEPDUPSPSQIBSNBDJTUCFGPSFUBLJOH-ZTPQBEPM
4QSBZ
t:PVTIPVMEOPUVTF-ZTPQBEPM4QSBZGPSNPSFUIBOEBZT*G
ZPVTUJMMIBWFTZNQUPNTBGUFSEBZTPSJGZPVIBWFBIJHI
GFWFSQMFBTFDPOTVMUBEPDUPS
t*GZPVIBWFMJWFSPSLJEOFZQSPCMFNTBTLZPVSEPDUPSCFGPSF
VTJOH-ZTPQBEPM4QSBZ
t-ZTPQBEPM4QSBZJTOPUTVJUBCMFGPSUIFUSFBUNFOUPGQBJOGVM
MFTJPOTJOUIFNPVUI FHVMDFSTPSTPSFT 
t*GZPVIBWFNPVUIVMDFSTQMFBTFDPOTVMUBEPDUPS
t4IPSUOFTTPGCSFBUI EZTQOPFB NBZCFPCTFSWFEEVFUPBO
VOEFSMZJOHDPOEJUJPO FHTXPMMFOUISPBU "OPUIFSSFBTPO
DPVMECFBGFFMJOHPGUJHIUOFTTJOUIFUISPBUEVFUPUIFMPDBM
BOBFTUIFUJDFGGFDUPG-ZTPQBEPM4QSBZ"GVSUIFSDBVTFDPVME
CFBOBMMFSHJDSFBDUJPOXIJDINBZBMTPDBVTFZPVSNPVUI
BOEUISPBUUPTXFMM
t:PVSUISPBUBOENPVUINBZGFFMMFTTTFOTJUJWFUIBOVTVBM
OVNC 
t5IFSFIBWFCFFOSFQPSUTPGTFWFSFTLJOSFBDUJPOTBTTPDJBUFE
XJUIUIFBENJOJTUSBUJPOPGBNCSPYPMIZESPDIMPSJEF*GZPV
EFWFMPQBTLJOSBTI JODMVEJOHMFTJPOTPGUIFNVDPVT
NFNCSBOFTTVDIBTNPVUIUISPBUOPTFFZFTHFOJUBMT TUPQ
VTJOH-ZTPQBEPM4QSBZBOEDPOUBDUZPVSEPDUPSJNNFEJBUFMZ
CHILDREN
%POPUHJWFUIJTNFEJDJOFUPDIJMESFOVOEFSZFBSTPGBHF
OTHER MEDICINES AND LYSOPADOL SPRAY
5FMMZPVSEPDUPSPSQ
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Lysopadol 17.86 mg/ml Oromucosal Spray, Solution
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One actuation of the spray contains 2.5 mg of ambroxol hydrochloride.
One ml of the spray contains 17.86 mg of ambroxol hydrochloride.
Excipient(s) with known effect:
This medicinal product contains small amounts of ethanol (alcohol), less than 100 mg per dose (4 actuations) and very
small amounts of propylene glycol.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Oromucosal spray, solution
Clear and almost colourless solution.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Pain relief in acute sore throat for adults and children over 12 years of age.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Adults and children over 12 years of age: one dose of 10 mg (4 actuations) to be sprayed into the back of the throat up
to 6 times per day.
Lysopadol 17.86 mg/ml Oromucosal Spray can be used for up to 3 days. In case of persistent symptoms or high fever,
the patient should consult a doctor.
_Paediatric population_
Lysopadol 17.86 mg/ml Oromucosal Spray should not be used in children under 12 years of age (see section 4.4).
Method of administration
Oromucosal use
Prior to use, the pump should be actuated 5 times so that an even spray mist is released. After not having used the spray
for a long time, the pump should be actuated once before applying the product again. For application the spray bottle
should be used in an upright position with the nozzle targeted at the back of the throat whilst pushing down the pump
head completely.
4.3 CONTRAINDICATIONS
Hypersensitivity to the active substance (ambroxol) or to any of the excipients listed in section 6.1.
HEALTH PRODUCTS REGULATORY A
                                
                                Soma hati kamili